CR10048A - Composiciones y métodos para inducir la activación de células dentricas a monociticas inmaduras - Google Patents

Composiciones y métodos para inducir la activación de células dentricas a monociticas inmaduras

Info

Publication number
CR10048A
CR10048A CR10048A CR10048A CR10048A CR 10048 A CR10048 A CR 10048A CR 10048 A CR10048 A CR 10048A CR 10048 A CR10048 A CR 10048A CR 10048 A CR10048 A CR 10048A
Authority
CR
Costa Rica
Prior art keywords
induce
methods
immature
monocitics
activation
Prior art date
Application number
CR10048A
Other languages
English (en)
Inventor
L Boynton Alton
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of CR10048A publication Critical patent/CR10048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El presente invento proporciona métodos para inducir la maduración de células dendríticas inmaduras (DC) y para activar esas células sin el uso de un agente de maduración para células dendríticas. Las DC activadas pueden usarse para inducir una respuesta de célula T específica para antígeno. Los métodos de invento también pueden comprender agregar un agente de maduración direccional, tal como gamma interferon, para inducir un TH-I y/o Th-2 en la respuesta obtenida.
CR10048A 2005-12-08 2008-06-05 Composiciones y métodos para inducir la activación de células dentricas a monociticas inmaduras CR10048A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74888505P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
CR10048A true CR10048A (es) 2008-09-17

Family

ID=38123555

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10048A CR10048A (es) 2005-12-08 2008-06-05 Composiciones y métodos para inducir la activación de células dentricas a monociticas inmaduras

Country Status (14)

Country Link
US (2) US20080254537A1 (es)
EP (3) EP3805367A1 (es)
JP (7) JP5954918B2 (es)
KR (6) KR20220113543A (es)
CN (2) CN103589684A (es)
AR (1) AR056851A1 (es)
AU (1) AU2006321794A1 (es)
BR (1) BRPI0619499A2 (es)
CA (1) CA2632263C (es)
CR (1) CR10048A (es)
IL (2) IL191930A (es)
RU (1) RU2008122550A (es)
TW (1) TW200800252A (es)
WO (1) WO2007067782A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2758834C (en) * 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
WO2011011688A2 (en) * 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
CA2777400C (en) 2009-10-12 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
US9476029B2 (en) * 2010-11-13 2016-10-25 Lung-Ji Chang Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
TWI503414B (zh) * 2012-07-05 2015-10-11 Fullhope Biomedical Co Ltd 一種製備專一性ｔ細胞之配方、方法及其配方製備方法
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
CN104981258B (zh) 2012-12-12 2017-10-20 奥比思健康解决方案有限责任公司 用于组织再生的组合物、其制备方法及其用途
SI2788474T1 (sl) * 2012-12-18 2016-01-29 Immunicum Ab Ko-diferenciacija monocitov iz alogenskih darovalcev
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
CN103800897B (zh) * 2014-03-12 2017-03-22 李金珍 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
WO2015199402A1 (ko) * 2014-06-23 2015-12-30 제이더블유크레아젠 주식회사 특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
JP6854290B2 (ja) * 2016-09-01 2021-04-07 株式会社理研免疫再生医学 ナチュラルキラーｔ（ｎｋｔ）細胞を刺激する樹状細胞の製造方法、ｎｋｔ細胞を刺激する樹状細胞、ｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物の製造方法およびｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物
JP2019528756A (ja) * 2016-09-29 2019-10-17 ハダシット メディカル リサーチ サービシズ アンド ディベロップメント リミテッド 樹状細胞調製物、その組成物及びその使用方法
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
JP6881333B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881332B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881331B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
EP4151224B1 (en) * 2020-05-15 2025-12-31 Seoul National University R & DB Foundation COMPOSITION TO IMPROVE THE IMMUNE RESPONSE THROUGH THE USE OF AN ACTIVATION FUNCTION OF DENDRITIC CELLS FROM STROMAL VASCULAR FRACTIONS ISOLATED FROM ADIPOSE TISSUES
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20010007659A1 (en) * 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN1713951B (zh) 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов

Also Published As

Publication number Publication date
KR20220113543A (ko) 2022-08-12
KR20080109717A (ko) 2008-12-17
JP2023171524A (ja) 2023-12-01
CN103589684A (zh) 2014-02-19
JP5954918B2 (ja) 2016-07-20
JP2019062904A (ja) 2019-04-25
EP3072958A1 (en) 2016-09-28
JP2013223517A (ja) 2013-10-31
US20080254537A1 (en) 2008-10-16
WO2007067782A3 (en) 2008-02-14
US20120244620A1 (en) 2012-09-27
CA2632263A1 (en) 2007-06-14
JP2009518045A (ja) 2009-05-07
KR20210013327A (ko) 2021-02-03
EP3805367A1 (en) 2021-04-14
EP1957634A4 (en) 2010-01-27
AR056851A1 (es) 2007-10-24
AU2006321794A1 (en) 2007-06-14
KR20150082688A (ko) 2015-07-15
KR20240005984A (ko) 2024-01-12
JP2021045176A (ja) 2021-03-25
IL229348B (en) 2018-12-31
EP1957634A2 (en) 2008-08-20
BRPI0619499A2 (pt) 2011-10-04
KR20180049169A (ko) 2018-05-10
IL229348A0 (en) 2013-12-31
IL191930A (en) 2013-11-28
TW200800252A (en) 2008-01-01
JP2016105725A (ja) 2016-06-16
JP2017158595A (ja) 2017-09-14
WO2007067782A2 (en) 2007-06-14
RU2008122550A (ru) 2010-01-20
CA2632263C (en) 2022-01-11
CN101336291A (zh) 2008-12-31
IL191930A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
CR10048A (es) Composiciones y métodos para inducir la activación de células dentricas a monociticas inmaduras
EP4461806A3 (en) Sc-b cells and compositions and methods for generating the same
CR9124A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
GT200500054A (es) Conjugados de caliqueamicina
AR069474A1 (es) Material anticorrosivo
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
ZA202109831B (en) Bioenergetic combinations and methods of using same
HN2005000803A (es) Formulaciones micronizadas en solventes organicos para preservacion de madera
AR058501A1 (es) Composiciones azeotropicas que comprenden 1,1,1,2,3- pentalfluoropeno y fluoruro de hidrogeno y sus usos
AR070850A1 (es) Dispositivo para mejorar un metodo de voladura
BRPI0821240A2 (pt) formas mutantes de estreptolisina o
WO2010062762A3 (en) Compositions and methods for reducing the signs of aging of the skin
MX2010005589A (es) Composicion para el cuidado personal.
EA201071166A1 (ru) Контролируемое высвобождение активных агентов из олеосом
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
BR112014014319A2 (pt) composições de cuidado oral
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
MX2011008816A (es) Formulacion ectoparasiticida con esencia mejorada.
CY1109209T1 (el) Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων
CL2004001473A1 (es) Procedimiento para producir neuronas desde celulas mesenquimatosas no diferenciadas y composicion que las contiene.
UY27739A1 (es) Células hospedantes que tienen propiedades mejoradas de supervivencia celular y métodos para generar estas células.
UY31012A1 (es) Formas solidas de la oxima de la (e)-1-(4-((1r, 2s, 3r)-1,2,3,4-tetrahidroixibutil)-1h-imidazol-2-il)etanona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)